ACE cardiovascular protection: EUROPA versus HOPE

Cardiovascular Drugs and Therapy

Volumn 18, Issue 3, 2004, Pages 179-180

  Boos, Christopher J ^a   Dawes, Matthew ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL; RAMIPRIL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; EDITORIAL; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STROKE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; GREAT BRITAIN; HUMANS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 3142709421     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CARD.0000033657.01493.6e     Document Type: Editorial

References (11)

1. Barton M, Haudenschild CC. Endothelium and atherogenesis: Endothelial therapy revisited. J Cardiovasc Pharmacol 2001;38 (Suppl 2):S23-S25.
2. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-2069.
3. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. Lancet 2000;355:1575-1581.
4. Wing L, Reid C, Ryan P, et al. for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting- enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-592.
5. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. AIPRD Study Group. Ann Intern Med 2003;139:244-252.
6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group
7. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. PROGRESS Collaborative Group. Lancet 2001;3581033-3581041.
8. Dzau, VJ, Bernstein, K, Celermajer, D, et al. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 2001 (Suppl.):1L-20L.
9. Dzau VJ, Bernstein K, Celermajer D, et al. Pathophysiologic and therapeutic importance of tissue ACE: A consensus report. Cardiovasc Drugs Ther 2002;16:149-160.
10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
11. The EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.